No announcement yet.

B.1.617 Lineage Report

  • Filter
  • Time
  • Show
Clear All
new posts

  • B.1.617 Lineage Report

    B.1.617 Lineage Report

    Accessed 16 April 2021

    Alaa Abdel Latif, Julia L. Mullen, Manar Alkuzweny, Ginger Tsueng, Marco Cano, Emily Haag, Jerry Zhou, Mark Zeller, Nate Matteson, Chunlei Wu, Kristian G. Andersen, Andrew I. Su, Karthik Gangavarapu, Laura D. Hughes, and the Center for Viral Systems Biology

    First identified in India
    Concerns surrounding new strains of SARS-CoV-2 (hCoV-19), the virus behind the COVID-19 pandemic, have been developing. This report outlines the prevalence of the B.1.617 lineage in the world, how it is changing over time, and how its prevalence varies across different locations.

    As of 16 April 2021 408 sequences in the B.1.617 lineage have been detected since the lineage was identified:
    B1.617 found
    location California, United States
    Total 6
    prevalence < 0.5%

  • #2
    I'm waiting for this to work :
    I check cog-uk daily for B.1.617 , E484Q etc.

    vaccine escape ?

    but only the antibody domain ab6 can neutralize
    the pseudo typed virus with the triple mutation (K417N, E484K, N501Y).

    Consistently, E484Q and E484D substitutions [13] analog to
    E484K, can also fully or partially escape ab8.

    Indian double mutant (L452R & E484Q), R408I, L455Y, K417G and E484K)
    have high docking score against ACE2 receptor compared with wild type and less docking score
    against antibody (CR3022) unlike wild type (Table2).

    Our in silico study
    suggests that the double mutant and K417G variants may severely affect the vaccine efficacy.


    Out of 7 variants, (India) double mutant have lowest binding energy against antibody

    ... newly emerged double mutant could significantly reduce the impact of the

    current vaccine

    I'm interested in expert panflu damage estimates
    my current links: ILI-charts: